Ketamine Therapy: Why Route Matters More Than Hype

If you’ve been following the conversation about ketamine therapy, you’ve probably noticed everyone’s got an opinion — from spa-style IV lounges to mail-order lozenges promising instant relief.

Let’s cut through the noise.

Ketamine is a powerful NMDA receptor antagonist that’s helped thousands of people — including first responders, healthcare workers, and veterans — finally find relief from treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). But here’s the thing: how it’s given matters just as much as the fact that it works.

And not all routes are created equal.

IV Ketamine: The Evidence Heavyweight

Let’s start with what we know best.

IV ketamine remains the gold standard in research — and for good reason. Administered at about 0.5 mg/kg over 30–40 minutes, IV infusions have been shown to reduce symptoms of depression and PTSD within 24 hours [1][2][3][4].

• For PTSD, a series of six infusions over two weeks produces robust and sustained improvement, with up to 67% of patients responding and relapse taking about 27 days on average [1][5][6][7][8][9].
• In treatment-resistant depression, IV ketamine helps even when multiple antidepressants have failed [3][10].

The side effects are short-lived — a little dizziness or mild dissociation that typically passes before you leave the chair [1][4][5][6][11].

But here’s the downside: IV requires medical monitoring, equipment, and a time commitment. For many first responders or healthcare professionals running on 12-hour shifts, that’s just not practical.

IM Ketamine: Reliable, Efficient, and Realistic

This is where intramuscular (IM) ketamine earns its stripes.

IM delivers the same medicine, the same mechanism — just in a simpler, more efficient way. You get a controlled dose, rapid onset, and sustained effect without the IV line or hours spent in a recliner.

Emerging studies show that IM ketamine provides comparable improvements in depression and PTSD symptoms, especially when used in a structured maintenance plan [9]. Patients experience steady relief and fewer logistical barriers, and providers can deliver care safely in an outpatient or integrative setting.

While the research base isn’t as large as for IV, the clinical outcomes are consistently strong — and for many, it’s the perfect middle ground between accessibility and evidence-based care.

In short: IM ketamine doesn’t need the hype. It just works — safely, efficiently, and sustainably.

Lozenges: Convenient, But Not Always Consistent

Now, let’s talk about oral and sublingual ketamine lozenges — the so-called “at-home” option.

They’ve gained popularity for maintenance therapy and accessibility, but the data paint a more cautious picture.

• Studies do show symptom reduction in depression and PTSD, but onset is slower (2–6 weeks) and the effect size is smaller compared to IV or IM [3][9].
• Blood absorption is highly variable — meaning some patients get excellent results, while others get very little.
• And while safety profiles are favorable, long-term outcomes and standardization remain under-studied [9].

For select patients already stabilized on other ketamine routes, lozenges can play a role in maintenance — but as a primary treatment, they’re often less predictable.

If you’re on the frontlines, juggling trauma exposure, high alertness, and irregular sleep, you probably don’t have time to wait six weeks to see if your body metabolized that lozenge properly.

Esketamine (Spravato): The Regulated Option

Esketamine, the intranasal cousin of ketamine (marketed as Spravato), holds the distinction of being FDA-approved for:

• Treatment-resistant depression, and
• Depression with acute suicidal ideation or behavior [12][10].

It’s administered in certified clinics and has strong data showing improved depressive symptoms and remission rates by week four [10].

Esketamine’s strength lies in its regulation and reproducibility, though the cost and clinic-only administration can be limiting.

What the Guidelines Say

According to the 2022 VA/DoD Clinical Practice Guideline, both ketamine and esketamine are appropriate for patients who haven’t improved with multiple antidepressants [10].

They’re not first-line therapies — but they are powerful, evidence-based tools for treatment-resistant depression and PTSD, especially when delivered responsibly and monitored for safety [5][10].

The Takeaway

All forms of ketamine have their place, but some deliver more consistent, reliable results than others.

• IV ketamine remains the best studied and fastest acting.
• IM ketamine offers the same efficacy in a more practical and accessible format — ideal for busy, high-stress professionals.
• Lozenges, while convenient, are best reserved for maintenance in established treatment plans, not as a standalone fix.
• Esketamine provides a regulated, insurance-backed pathway for those who qualify.

Across all routes, ketamine remains well tolerated and safe, with transient side effects and strong clinical promise [1][3][5][6][9][10][11][13].

If you’ve spent your career taking care of others — whether on an ambulance, in an ER, or behind a badge — it might be time to explore what science-backed, clinician-guided ketamine therapy can do for you.

Because recovery shouldn’t require a hospital stay — just the right route.

References

1. Feder A, Costi S, Rutter SB, et al. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021;178(2):193-202.
2. Price RB, Kissel N, Baumeister A, et al. International Pooled Patient-Level Meta-Analysis of Ketamine Infusion for Depression. Mol Psychiatry. 2022;27(12):5096-5112.
3. Marwaha S, Palmer E, Suppes T, et al. Novel and Emerging Treatments for Major Depression. Lancet. 2023;401(10371):141-153.
4. Feder A, Parides MK, Murrough JW, et al. Efficacy of Intravenous Ketamine for Treatment of Chronic PTSD. JAMA Psychiatry. 2014;71(6):681-688.
5. Sicignano DJ, Kurschner R, Weisman N, et al. The Impact of Ketamine for Treatment of PTSD: A Systematic Review With Meta-Analyses. Ann Pharmacother. 2024;58(7):669-677.
6. McInnes LA, Berman RM, Worley M, Shih E. A Retrospective Analysis of Ketamine IV Therapy for PTSD in Real-World Settings. Psychiatry Res. 2025;352:116689.
7. Kwan ATH, Lakhani M, Singh G, et al. Ketamine for the Treatment of Psychiatric Disorders: A Systematic Review and Meta-Analysis. CNS Spectr. 2024;1-8.
8. Norbury A, Rutter SB, Collins AB, et al. Neuroimaging Correlates and Predictors of Response to Repeated-Dose IV Ketamine in PTSD. Neuropsychopharmacology. 2021;46(13):2266-2277.
9. Liu JJW, Ein N, Gervasio J, et al. Ketamine in the Effective Management of Chronic Pain, Depression, and PTSD for Veterans: A Meta-Analysis. Front Psychiatry. 2024;15:1338581.
10. McQuaid JR, Buelt A, Capaldi V, et al. The Management of Major Depressive Disorder: Synopsis of the 2022 VA/DoD Guideline. Ann Intern Med. 2022;175(10):1440-1451.
11. Jumaili WA, Trivedi C, Chao T, Kubosumi A, Jain S. Safety and Efficacy of Ketamine as a Therapeutic Intervention for PTSD. Behav Brain Res. 2022;424:113804.
12. FDA Orange Book. U.S. Food and Drug Administration.
13. Albuquerque TR, Macedo LFR, Delmondes GA, et al. Evidence for the Beneficial Effect of Ketamine in PTSD: A Systematic Review and Meta-Analysis. J Cereb Blood Flow Metab. 2022;42(12):2175-2187.